SCHEDULE: Octagon Capital Discloses 4.7% Stake in Unicycive Therapeutics

Octagon Capital Advisors LP and affiliated funds, along with Ting Jia, reported a combined 4.7% passive ownership stake in Unicycive Therapeutics, Inc. as of December 31, 2025.

Summary

• Octagon Capital Advisors LP, Octagon Investments Master Fund LP, Octagon Biotech Opportunities Fund I LP, and Ting Jia (collectively 'Reporting Persons') filed an Amendment No. 3 to Schedule 13G.
• The filing reports beneficial ownership of Common Stock in Unicycive Therapeutics, Inc. (CUSIP: 90466Y202).
• Octagon Capital Advisors LP and Ting Jia each beneficially own 1,000,000 shares, representing 4.7% of the class.
• Octagon Investments Master Fund LP beneficially owns 650,000 shares, representing 3.0% of the class.
• Octagon Biotech Opportunities Fund I LP beneficially owns 350,000 shares, representing 1.7% of the class.
• The percentages are calculated based on 21,491,396 Common Shares outstanding as of November 12, 2025.
• The shares are held in the ordinary course of business and not for the purpose of changing or influencing control of the issuer.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral to slightly positive filing. It confirms a significant, passive institutional stake, which can be seen as a vote of confidence, but provides no new operational or financial insights.

Positives

• A significant institutional investor group, Octagon Capital Advisors LP and its affiliates, maintains a substantial stake in Unicycive Therapeutics, indicating continued confidence.
• The filing explicitly states the shares were acquired and are held in the ordinary course of business, not for control purposes, suggesting a passive investment strategy.

Future Outlook

This filing does not contain forward-looking statements or guidance from the issuer. It is a disclosure of current ownership by an institutional investor group.

Management Comments

• "The securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities."

Industry Context

StockSavvy.ai notes that institutional filings like this Schedule 13G provide transparency into significant ownership stakes, which can sometimes signal investor confidence in a company within the biotechnology sector. While this filing is purely a disclosure, the continued presence of Octagon Capital Advisors, an investment manager, suggests ongoing interest in Unicycive Therapeutics.

Comparison to Industry Standards

• This filing is a standard disclosure of beneficial ownership by a passive investor group, adhering to SEC regulations for Schedule 13G.
• The reported ownership percentages are typical for institutional investors taking a passive stake in publicly traded companies, particularly in the biotech sector where specialized funds often invest.
• No specific comparable companies or projects are mentioned in this filing to allow for a direct comparison of results.

Stakeholder Impact

• Shareholders: Provides transparency regarding a significant institutional holder's stake, potentially influencing market perception of stability or institutional interest.
• Management: Awareness of a large, passive institutional investor on the shareholder register.

Key Dates

Recommendation

This Schedule 13G filing is a routine disclosure of a passive ownership stake by an institutional investor group. It does not contain new operational, financial, or strategic information that would warrant a change in investment thesis. The confirmation of a significant, passive stake by Octagon Capital Advisors and its affiliates suggests continued institutional interest but provides no catalysts for a 'buy' or 'sell' recommendation. Therefore, a 'hold' recommendation is appropriate as investors await further fundamental news from Unicycive Therapeutics.

Keywords

Unicycive Therapeutics, Octagon Capital Advisors, Schedule 13G, Beneficial Ownership, Common Stock, Institutional Investor, Biotech, Pharmaceuticals